/C O R R E C T I O N -- VMT Scientific, Inc./
December 05 2005 - 9:00AM
PR Newswire (US)
In the news release, VMT Scientific, Inc. (OTC: VMTF) Announces
Proof of Concept Testing to Start, issued Friday, Dec. 2, by VMT
Scientific, Inc. over PR Newswire, we are advised by the company
that the last sentence of the first paragraph should read "We
encourage everyone to visit http://www.vmtf.org to see more details
on our technology." which was previously omitted. Complete,
corrected release follows: LAS VEGAS, Dec. 2 /PRNewswire-FirstCall/
-- VMT Scientific Inc. (OTC:VMTF) VMT Scientific announces
accomplishment of its second step in its accelerated timeline, to
meet public and professional pressure for our technology. We are
proud to announce the development of our upper extremity prototype
is completed. Our PROOF OF CONCEPT TESTING IS EXPECTED TO BE
COMPLETED BY THE END OF THE FIRST QUARTER 2006. "If these tests
prove scientifically positive," states VMT's CTO, "we would expect
to have several major medical research centers and companies
requesting our data be privately presented to them for review." We
are hoping that this will lead us to potential PRE-LICENSING
NEGOTIATIONS, joint venturing and/or additional technology
development of new applications for our patented technology. We
encourage everyone to visit http://www.vmtf.org/ to see more
details on our technology. This Press Release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
You should not place undue reliance on these forward-looking
statements. These statements involve risks and uncertainties that
could cause actual results to differ materially from those
suggested in the forward- looking statements, particularly those
risks and uncertainties inherent in the process of developing,
medical products and Clinical trials. Factors that may cause such a
difference include risks related to VMT Scientific Inc.'s limited
operating history, risks associated with completing development and
obtaining FDA medical approvals, successful patent protection and
prosecution, successful sale of licensed technology nationally or
internationally. VMT Scientific technology will not meet with
market acceptance, the risk of future warranty and product
liability claims, the uncertainty of VMT Scientifics' future access
to capital to sustain operations, achieve profitability or continue
as a going concern, the failure by VMT Scientific to secure and
maintain relationships with suppliers, manufacturers and other
third parties, reliance on key employees, and dependence on
intellectual property. These forward-looking statements are based
on information and management's expectations as of the date hereof.
Future results may differ materially from our current expectations.
DATASOURCE: VMT Scientific, Inc. CONTACT: Catherine S. Ratelle,
Director of Operations, VMT Scientific, Inc., +1-702-990-3477 Web
site: http://www.vmtf.org/
Copyright